Skip to main content

Investor RelationsWealth Management:  CA  |  UK  |  AU

Menu
Privia Health
US$117.5m

Canaccord Genuity Acts as Passive Bookrunner to Privia Health on its US$117.5m Follow-On Offering

Press Releases
Lead Transaction Banker

More like this

Eleusis Therapeutics
Pending Completion

Eleusis Therapeutics

Exclusive Financial Advisor (Sell side)
View transaction detail
Privia Health
US$117.5m
November 2022

Privia Health

Passive Bookrunner (Follow-On)
View transaction detail
Akero Therapeutics, Inc.
US$230m
September 2022

Akero Therapeutics, Inc.

Lead Manager (Follow-On)
View transaction detail

How can we help?

If you would like to find out more about Canaccord Genuity or any of our services, please get in touch.